title: [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
abstract: The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse. Temozolomide was administered orally once daily for the first five days of a 28-day cycle, at a dose of 150 or 200 mg/m(2)/day. The response rate determined by independent central review of MRI was 34% (95% confidence interval: 18.6%-53.2%), with 3 complete response and 8 partial response. The rate of "no change or better" was 91% (95% confidence interval: 75.0%-98.0%). Progression-free survival (PFS) at 6 months was 40.6%, and the median PFS was 4.1 months. The incidence of constipation (50%) and nausea (25%) was high,but these events were all mild or moderate in severity except in one subject with constipation,and could be managed with standard laxatives and antiemetics. The main laboratory test abnormalities (total incidence and incidence of grade 3/4 change) were lymphocytopenia (50%, 25%), neutropenia (47%, 6%), leukopenia (38%, 3%), thrombocytopenia (31%, 9%), and increased GPT (25%, 3%). Temozolomide was shown to have good efficacy and tolerability in patients with anaplastic astrocytoma at first relapse.
authors.affiliation: Dept. of Neurosurgery, Saitama Medical University.
authors.forename: Ryo
authors.initials: R
authors.lastname: Nishikawa
authors.forename: Soichiro
authors.initials: S
authors.lastname: Shibui
authors.forename: Motohiko
authors.initials: M
authors.lastname: Maruno
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Sugiyama
authors.forename: Shinya
authors.initials: S
authors.lastname: Sato
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Fujimaki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Wakabayashi
authors.forename: Jun
authors.initials: J
authors.lastname: Takahashi
authors.forename: Masato
authors.initials: M
authors.lastname: Kochi
authors.forename: Hideo
authors.initials: H
authors.lastname: Nakamura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Sawamura
authors.forename: Jun
authors.initials: J
authors.lastname: Ikeda
authors.forename: Tomokatsu
authors.initials: T
authors.lastname: Hori
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Aoki
authors.forename: Masao
authors.initials: M
authors.lastname: Matsutani
mesh_terms: D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide